There are currently 189 clinical trials in Hollywood, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Memorial Healthcare System, GSK Investigational Site and Memorial Cancer Institute at Memorial Regional Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Intracranial Meningioma, Grade 2 Meningioma
Register for Updates
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2025
Locations: Site 42, Hollywood, Florida
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/05/2025
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: The Medici Medical Research, Hollywood, Florida +1 locations
Conditions: Ulcerative Colitis
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2025
Locations: Feinstein Dermatology and Cosmetic Surgery, Hollywood, Florida
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
NCT06945458
Recruiting
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/01/2025
Locations: Kymera Investigative Site, Hollywood, Florida
Conditions: Atopic Dermatitis
Register for Updates
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
NCT06564818
Recruiting
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/28/2025
Locations: Research Centers of America, Hollywood, Florida
Conditions: Major Depressive Disorder
Register for Updates
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
NCT06455475
Recruiting
This randomized controlled study evaluates the adjuvant use of Derm-Maxx in patients with diabetic foot ulcers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Royal Research, Hollywood, Florida
Conditions: Diabetic Foot Ulcer
Register for Updates
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Recruiting
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282
Recruiting
This multicenter, single arm, prospective, non-randomized study is designed to evaluate the safety and effectiveness of The Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in pre-mature infants over a period of 6 months.
Gender:
ALL
Ages:
5 days and above
Trial Updated:
04/24/2025
Locations: Memorial Healthcare System-Joe DiMaggio Children's Hospital, Hollywood, Florida
Conditions: Patent Ductus Arteriosus (PDA)
Register for Updates
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964
Recruiting
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
04/23/2025
Locations: Site 5060, Hollywood, Florida
Conditions: Schizophrenia, Cognitive Impairment
Register for Updates
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
NCT06630117
Recruiting
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/17/2025
Locations: Research Centers of America ( Hollywood ) ( Site 0004), Hollywood, Florida
Conditions: Healthy
Register for Updates